menu
    • menu

    Company profile for CinRx Pharma

    NEW Drugs in Dev: 3
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    CinRx is a biotechnology company founded in 2015 that leverages its team’s exceptional industry experience to develop therapeutics in a novel way that meets the modern paradigm of drug development. CinRx acquires compounds from multiple sources, as well as partners with other biotechnology companies, to invest in and develop innovative products that will transform the lives of patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CinRx PharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    5375 Medpace Way Cincinnati, OH 45227
    Telephone
    Telephone
    844-531-1834
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.cinrx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/cinrx-pharma/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/CinRx_Pharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CinDome Doses 1st Patient in Ph2 of CIN-102 for Gastroparesis
    CinDome Doses 1st Patient in Ph2 of CIN-102 for Gastroparesis

    04 Jun 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250604187126/en/CinDome-Pharma-Announces-First-Patient-Dosed-in-the-envisionGI-Phase-2-Clinical-Trial-of-Deudomperidone-CIN-102-for-the-Treatment-of-Idiopathic-Gastroparesis

    BUSINESSWIRE
    04 Jun 2025
    Share Share
    CinFina Pharma Presents Positive Phase 1 Results at ObesityWeek®
    CinFina Pharma Presents Positive Phase 1 Results at ObesityWeek®

    03 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241103849127/en

    BUSINESSWIRE
    03 Nov 2024
    Share Share
    CinFina Pharma Presents Posters at ObesityWeek® 2024
    CinFina Pharma Presents Posters at ObesityWeek® 2024

    23 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241023114095/en

    BUSINESSWIRE
    23 Oct 2024
    Share Share
    CinRx Pharma Announces Additional $73 Million Financing
    CinRx Pharma Announces Additional $73 Million Financing

    30 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240530932802/en

    BUSINESSWIRE
    30 May 2024
    Share Share
    CinDome Pharma Announces $40 Million Series B Extension
    CinDome Pharma Announces $40 Million Series B Extension

    16 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240516063766/en

    BUSINESSWIRE
    16 May 2024
    Share Share
    CinFina Announces FDA Clearance of NDA Ph 1 Trial for the Treatment of Obesity
    CinFina Announces FDA Clearance of NDA Ph 1 Trial for the Treatment of Obesity

    26 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240326703050/en

    BUSINESSWIRE
    26 Mar 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search